Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Varlilumab (Primary) ; Cyclophosphamide; Montanide ISA-51; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Mel-65
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 29 Oct 2018.
- 14 Aug 2018 New trial record